|Bid||5.20 x 3100|
|Ask||5.21 x 1300|
|Day's Range||5.17 - 5.32|
|52 Week Range||2.50 - 6.79|
|Beta (5Y Monthly)||1.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 27, 2021 - Nov 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
Subscribe to Yahoo Finance Plus to view Fair Value for AGENLearn more
Agenus , an oncology drug manufacturer, is a good candidate for a simple covered call strategy, argues Real Money's Bret Jensen. This strategy is cheap for investors since the fees for option orders have declined a lot at the majority of brokerages, according to Jensen. "This strategy provides significant downside protection to most holdings within my portfolio," Jensen wrote recently on Real Money.
LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million cash
Few diseases have wreaked as much havoc as malaria. In 2019, there were an estimated 229 million malaria cases. Last week, the World Health Organization (WHO) recommended widespread use of a malaria vaccine in children.